ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/API/Dalareline
C56H78N16O12
1167.3 g/mol
APIDanger

Surfagon

CAS52435-06-0
Category
API
Compound Class
Peptide
Primary Use
Pharmaceutical Raw Material

Surfagon is a synthetic peptide compound that acts as a luteinizing hormone-releasing hormone (LHRH) agonist. It is used as an active pharmaceutical ingredient in the manufacturing of products for research and laboratory applications.

Pharmaceutical raw material for LHRH agonist productionResearch compound for peptide hormone studies

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing Surfagon?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

StrongStructure SimilarSimilarity 0.92

6-D-ala-gonadorelin

CAS51230-19-4

pharmaceutical raw material

StrongStructure SimilarSimilarity 0.92

Fertirelin acetate

CAS66002-66-2

pharmaceutical raw material

StrongStructure SimilarSimilarity 0.92

Fertirelin

CAS38234-21-8

pharmaceutical raw material

ReferenceSame Category

(5alpha)-4,5-Epoxy-3,14-dihydroxymorphinan-6-one hydrochloride

CAS52446-24-9

pharmaceutical raw material

ReferenceSame Category

Flunarizine

CAS52468-60-7

pharmaceutical raw material

ReferenceSame Category

Buprenorphine

CAS52485-79-7

pharmaceutical raw material

ReferenceSame Category

L-3372

CAS52490-15-0

pharmaceutical raw material

Referencestereoisomer of

Alarelin

CAS79561-22-1

pharmaceutical raw material

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more

Safety Reference

Health Hazard
Health Hazard
Danger
H360May damage fertility or the unborn child
Identifiers
IUPAC Name

N-[(2S)-1-[[(2S)-1-[[1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide

InChIKey

QLGKMLRGKPKGKI-MUVLZESKSA-N

SMILES

CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)C6CCC(=O)N6

Synonyms (14)
  • AY-25,205
  • Ala-Pro-NHET-LHRH
  • Dalareline
  • GnRH, Ala(6)-N-Et-ProNH2(9)-
  • LHRH, Ala(6)-N-Et-ProNH2(9)-
  • Surfagon
  • leuprolide IS

Sourcing Surfagon?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→